南通直流调速实训控制柜(鞍山通用智能型电工电子电拖三合一实验台) (今日更新中)

HAVANA, Sept. 6 (Xinhua) -- Cuban medical authorities have launched the sales of the world's first therapeutic vaccine against lung cancer, local officials said on Tuesday.The CimaVax-EGF vaccine, as a result of a 25-year research into diseases related to tobacco smoking, has been developed by researchers and scientists at the Center of Molecular Immunology (CIM) in Havana.The active drug ingredient in the vaccine is based on "a protein we all have when cancer is uncontrolled." "The epidermal growth factor is related to all cell proliferation," said Gisela Gonzalez, head researcher of the project."The drug could turn the cancer into a manageable, chronic disease by generating antibodies against the proteins which triggered the uncontrolled cell proliferation," she said.The immunogenic vaccine is appropriate to patients with advanced lung cancer in stages of three and four, showing no positive response to other kinds of treatments such as chemotherapy and radiotherapy, the expert said."It is not possible to prevent the disease but this vaccine improves significantly the status of the critically ill patients," she added.She said the CimaVax-EGF has gone through clinical studies and trials in over 1,000 patients across the island and is currently distributed free of charge in all hospitals of the Caribbean island nation.Gonzalez also said researchers at the CIM planned to use the same principle of the CimaVax-EGF in treating other cancerous tumors such as prostate, uterus and breast cancers.Lung cancer is regarded as one of the world's most serious, common and deadly cancers and is most frequently found among tobacco smokers.According to the World Health Organization, the disease generally kills 5 million people a year, and the figure is expected to rise to as much as 8 million by 2030 unless smoking habits are changed.In Cuba, like many other developing countries across the world, smoking is seen as a status symbol. Lung cancer, killing about 20,000 people a year in the Caribbean country, is considered a serious threat to public health and the leading cause of death in 12 of the country's 15 provinces.

BEIJING, Sept. 24 (Xinhuanet) -- The city government called on residents to register their dogs on time and keep better control of them to fight the increasing number of rabies cases during a discussion of the Beijing Municipal People's Congress on Friday."As the number of dogs in the city rises, the number of dog bites is also going up," said Lei Decai, director of the rural affairs committee of the people's congress.Last year, more than 30,000 residents were bitten by dogs and nine died of rabies. As of June this year, six people have died of rabies, Lei said."The main problem lies in the registration of dogs," he said, adding that the number of unlicensed dogs in the city is unknown. A man takes his dog for a spin on the back of a motorized tricycle in a Beijing street last month. The city plans to strengthen management of dogs in the future in an effort to combat the spread of rabies, which can be fatal if it is not treated in timeAt the beginning of June, eight residents were attacked by dogs in Beijing's Olympic Forest Park.One of them, Zhao Haiyan, 56, a retiree, was bitten in her left leg as she walked in the park. The puncture wounds left her leg bleeding."An officer in the park brought me to a hospital to get vaccinated for rabies, and I had no idea who I could ask for compensation, because the dog was fed by workers in a construction site and had no registration," she told China Daily."Now I worry when I see an unleashed dog," she added.Zhao is not alone. Cao Lifang, also 56, has helped a friend care for a dog since February. Dabai, a 6-year-old male Samoyed, bit her in mid-June when she was trying to keep him from fighting another dog.The attack left a deep bite mark on Cao's left hand, and she had to take anti-rabies injections for more than a month.

WASHINGTON, July 20 (Xinhua) -- The loss of a protein that coats sperm may explain a significant proportion of infertility in men worldwide, according to a study by an international team of researchers led by University of California Davis.A paper describing the work was published Wednesday in the journal Science Translational Medicine. The research could open up new ways to screen and treat couples for infertility.The gene DEFB126 encodes a protein called Beta Defensin 126, which coats the surface of sperm and helps it penetrate cervical mucus in the female. A survey of samples from the U.S., Britain and China showed that as many as a quarter of men worldwide carry two copies of the defective gene.In the new study, researchers found that men with a muted DEFB126 lack Beta Defensin 126, making it much more difficult for sperm to swim through the mucus and eventually join with an egg.Examining 500 newly married Chinese couples, researchers found that the lack of Beta Defensin 126 in men with the DEFB126 mutation lowered fertility (even among men that did not display other deficiencies usually associated with infertility, like inadequate semen volume and low sperm motility). Wives of men with the Beta Defensin 126 variant were significantly less likely to become pregnant than were other couples, and 30 percent less likely to have a birth.This genetic variation in DEFB126 likely accounts for many unexplained cases of infertility, researchers say. They hope next to work with a major infertility program in the U.S. to further explore the role of the mutation.

BEIJING, Aug. 30 (Xinhuanet) -- The search giant Google admits it sees the new Google+ social network as an "identity service" or platform on which it can build other products, according to media reports.Google chariman Eric Schmidt said Google isn't interested in changing its policies to accommodate users such as political dissidents or others who prefer to remain anonymous: If people want to remain anonymous, then they shouldn't use Google+."Fundamentally, [Google+] depends on people using their real names if they're going to build future products that leverage that information," NPR's Andy Carvin wrote in a post on Google+ as he paraphrased Schmidt's remarks.Critics say the move is harmful to political activists, victims of harassment and numerous other groups for whom using a real name online might pose a safety risk, according to CNN reports."Regarding people who are concerned about their safety, [Schmidt] said G+ is completely optional," Carvin wrote.Meanwhile, according to Carvin, Schmidt also said "the Internet would be better if we knew you were a real person rather than a dog or a fake person. Some people are just evil and we should be able to ID them and rank them downward."

WASHINGTON, Sept. 12 (Xinhua) -- An enzyme that appears to play a role in controlling the brain's response to nicotine and alcohol in mice might be a promising target for a drug that simultaneously would treat nicotine addiction and alcohol abuse in people, U.S. researchers find.Over the course of four weeks, mice genetically engineered to lack the gene for protein kinase C (PKC) epsilon consumed less of a nicotine-containing water solution than normal mice, and were less likely to return to a chamber in which they had been given nicotine. In contrast, normal mice steadily increased their consumption of nicotine solution while the mice lacking PKC epsilon did not.The study conducted by researchers at the Ernest Gallo Clinic and Research Center, affiliated with the University of California, San Francisco, appeared Monday in the online edition of the Proceedings of the National Academy of Sciences.In normal mice, as in humans, nicotine binds to a certain class of nicotinic receptors located on dopamine neurons, which causes dopamine to be released in the brain. Dopamine creates a feeling of enjoyment, and thus prompts a sense of reward. Researchers found that mice lacking PKC epsilon are deficient in these nicotinic receptors.The finding complements earlier research in which researchers found that mice genetically engineered to lack the PKC epsilon enzyme drank less alcohol than normal mice and were disinclined to return to a chamber in which they had been given alcohol."This could mean that these mice might not get the same sense of reward from nicotine or alcohol," said Gallo senior associate director and investigator Robert Messing. "The enzyme looks like it regulates the part of the reward system that involves these nicotinic receptors."The reward system is a complex of areas in the brain that affect craving for nicotine, alcohol and other addictive substances.The next step in the research, said Messing, would be to develop compounds that inhibit PKC epsilon. The ultimate goal, he added, would be medications that could be used "to take the edge off of addiction by helping people get over some of their reward craving."

来源：资阳报